Inspire Medical Systems (INSP) Osake Kurssi

Inspire Medical Systems Inc is primarily active in the medical device industry.

The main competitors of Inspire Medical Systems Inc in the market include Medtronic, Inc., Intuitive Surgical, Inc., ResMed Inc., and Fisher & Paykel Healthcare Corporation Limited.

Inspire Medical Systems Inc, a renowned medical technology company, was founded in 2007 by Professor Philip R. Westbrook and Dr. Timothy A. Meyer. The company is headquartered in Maple Grove, Minnesota, USA. Inspire Medical Systems is dedicated to developing innovative solutions for the treatment of obstructive sleep apnea (OSA). The company introduced the Inspire therapy, an FDA-approved neurostimulation technology that provides a safe and effective alternative to traditional OSA treatments. With a mission to enhance the quality of life for patients suffering from OSA, Inspire Medical Systems has gained recognition as a leader in the field of sleep apnea treatment solutions.

Some significant milestones achieved by Inspire Medical Systems Inc include the successful completion of multiple clinical trials and obtaining FDA approval for their innovative Inspire therapy. The company has also undergone successful IPOs and has expanded its market presence globally. Moreover, Inspire Medical Systems Inc has received numerous awards and recognitions for their revolutionary advancements in the treatment of obstructive sleep apnea. These milestones showcase the company's commitment to innovation, improving patient outcomes, and establishing itself as a leader in the medical technology industry.

Inspire Medical Systems Inc primarily operates in the United States and Europe. The company's innovative products and therapies are focused on treating obstructive sleep apnea (OSA). Through their unique airway stimulation technology, Inspire Medical Systems Inc provides solutions to help patients with OSA improve their sleep quality and overall well-being. With a strong presence in these key regions, Inspire Medical Systems Inc continues to expand its reach and provide effective treatment options for individuals suffering from sleep apnea.

Inspire Medical Systems Inc represents a commitment to improving the lives of individuals suffering from sleep apnea. Their corporate philosophy revolves around innovation, patient-centricity, and delivering effective and reliable solutions. By combining advanced technology with clinical expertise, Inspire Medical Systems Inc offers an innovative therapy that provides significant benefits to patients. The company emphasizes quality and excellence in everything they do, ensuring that their products meet the highest standards in terms of effectiveness and patient safety. With their dedication to improving the lives of those affected by sleep apnea, Inspire Medical Systems Inc strives to be a leader in the field of medical device solutions.

Analyytikot asettavat tällä hetkellä Inspire Medical Systems-osakkeelle keskimääräisen tavoitehinnan 60,30 USD (mediaani: 60,00 USD), mikä merkitsee −16,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 24 analyytikkoarvioon.

Inspire Medical Systems Analyytikkojen kursstavoitteet 2026

24 analyytikkoa arvioi tällä hetkellä Inspire Medical Systems-osaketta: 9 suosittaa ostoa, 13 pitoa ja 2 myyntiä. Vuodelle 2026 analyytikot odottavat Inspire Medical Systems-yhtiöltä 853,84 M USD liikevaihtoa ja 1,23 USD osakekohtaista tulosta.

Inspire Medical Systems Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Inspire Medical Systems-osake noteerataan hintaan 64,25 EUR (71,78 USD).

Inspire Medical Systems-osake (INSP) on listattuna 3 pörssissä, muun muassa: NYSE (INSP), Frankfurt (2DR.F), München (2DR.MU).

Inspire Medical Systems Inc is a leading provider of innovative medical products for the treatment of sleep apnea. The company is headquartered in Minneapolis, MN and was founded in 2007. It is listed on the New York Stock Exchange (NYSE: INSP). Inspire Medical Systems offers an innovative therapy that uses selective neurostimulation to open the patient's airways during sleep and regulate breathing. The Inspire system consists of a small, implantable stimulation unit that is attached to the chest muscle, a sensor implanted in the chest muscle, and a remote control that the patient uses to turn the system on and off. The company holds a variety of patents in this field and works closely with leading doctors and sleep experts to ensure the effectiveness and safety of the system. The Inspire system is currently available in the United States, Canada, and Europe. In addition to the main product of the Inspire system, the company also offers a variety of therapy and support services to help patients with their sleep apnea treatment. These services include telephone support, training programs, and assistance with billing. Inspire Medical Systems' business model is based on a highly focused market approach. The company targets patients who suffer from severe sleep apnea and have not had success with conventional treatment methods, such as CPAP therapy. Based on market research data, the company estimates that there are up to 2 million potential patients in the US alone who could benefit from the Inspire system. Inspire Medical Systems has also focused on an intensive sales strategy. The company has built a distribution structure that aims to collaborate closely with sleep centers to promote the adoption and use of the system. An important part of this strategy is training doctors and medical staff to ensure they are familiar with the system and can apply it correctly. In terms of financial performance, Inspire Medical Systems has solid indicators. In 2019, the company reported revenue of $162.5 million, a 65% increase from the previous year. The company's success is also reflected in its market capitalization, which is approximately $4 billion. Overall, the business model of Inspire Medical Systems is highly focused and targeted towards a niche in the healthcare market. The company has developed an innovative product and is intensifying its efforts to penetrate the market and promote the use of its system.

odotettu liikevaihto Inspire Medical Systems on 853,84 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Inspire Medical Systems on 36,01 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Inspire Medical Systems:n hinta-voitto-suhde (P/E) on tällä hetkellä 58,25. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Inspire Medical Systems-osakkeen arvostusta.

Inspire Medical Systems:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,46. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Inspire Medical Systems-osakkeen arvostuskennuslukuna.

Inspire Medical Systems:n Eulpool-laatuscore on 7/10.

Inspire Medical Systems:n ISIN on US4577301090. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Inspire Medical Systems:n WKN on A2JLEP. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Inspire Medical Systems:n ticker on INSP. Tämä pörssinoteeraus käytetään Inspire Medical Systems-osakkeiden kauppaan pörssissä.